By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has signed an agreement with BioMarin Pharmaceutical to perform BRCA1 and BRCA 2 mutation testing for the drug firm's PARP inhibitor drug candidate, Myriad said after the close of the market on Wednesday.

The testing will be done on patients enrolled in BioMarin's Phase I and Phase II clinical study of its PARP inhibitor called BMN 673 for patients with advanced or recurrent tumors.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.